Delivery Order SPE2DB22D3016-SPE2DB25FBFA6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $19,253.01 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical supplies. The contract, executed on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing and represents a non-set-aside competitive award. Performance will be conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at approximately $51,886 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen (162 mg/0.9 mL) pharmaceutical product, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract was issued on July 24, 2025, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The award includes no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $18,202.15 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed price delivery order, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the company's role as a...
- The Defense Logistics Agency awarded a $48,698.09 delivery order to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical supplies. This firm fixed price, competitively awarded contract was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,672.79 for Actemra Actpen 162 mg/0.9 mL pharmaceutical product, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $7,609.13 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical product. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 30, 2025. The award was made on July 29, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $32,838.00 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,966.67 by the Defense Logistics Agency (DLA) on August 15, 2025, with an ultimate completion date of August 18, 2025. The contract is for the supply of Actemra ActPen 162 mg/0.9 ml pharmaceutical product under firm fixed pricing with no set-aside designation. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBFA6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,058.52 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL injectable medication. Issued on August 14, 2025, with an ultimate completion date of August 15, 2025, this firm fixed-price contract requires performance at the company's Conshohocken, Pennsylvania location. The award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order represents a task order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs globally, including support for the Defense Health Agency and other federal healthcare systems. The company's contract portfolio with DLA reflects its role as a critical vendor for federal medical procurement, particularly for specialty medications and brand-name pharmaceuticals across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 8/14/25 |